Trials / Active Not Recruiting
Active Not RecruitingNCT06096025
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Methodist Health System · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.
Detailed description
The Infectious Diseases Society of America (IDSA) guidelines for CAP management advocate for short courses of antibiotics for CAP treatment. However, it does not address duration of therapy for common CAP pathogens such as S. pneumoniae when associated with blood stream infections (BSI). 3 Currently, GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus.4 Additionally, lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice. Most randomized clinical trials as well as retrospective studies on treatment duration, have been conducted mainly in gram-negative BSI
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pneumoniae bacteremia therapy | To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia. |
Timeline
- Start date
- 2023-06-23
- Primary completion
- 2026-06-23
- Completion
- 2026-06-23
- First posted
- 2023-10-23
- Last updated
- 2025-07-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06096025. Inclusion in this directory is not an endorsement.